Background {#s1}
==========

Chromatin structure of histone has two forms such as Histone acetylases (HATs) and Histone deacetylases (HDACs). The acetylation status of histone operated by histone acetylases and histone deacetylases, which are in equilibrium [@R01].The main function of HDAC is deacetylation of e-amino groups of lysine located near the amino terminal of core histone proteins and restore positive charge on lysine residue, which results in tightening of nucleosome structure and gene silencing [@R02]. HDACs not only deacetylate the histone proteins, but also deacetylate non-histone proteins, such as p53 and GATA-1 [@R03]. Histone deacetylase protein belongs to the hydrolase family and classified into two classes on the basis of sequence similarity, class I has four isomers of HDAC1- 3, and HDAC8 and are related to yeast Rpd3 gene, class II has six isomers of HDAC4-7 and HDAC9-10 and are related to Hda1 and class I and II operated by zinc dependent mechanism [@R04]. Histone deacetylases (HDACs) control the gene expression and cellular signalling and histone deacetylases 2 (HDAC2) is over expressed in solid tumors including colon cancer, lung cancer, cervical carcinoma, breast cancer, and kidney/cervix cancer and also in Alzheimer\'s disease [@R05]-[@R07]. Several natural and synthetic derivatives have been identified to be able to inhibit the activity of the HDACs.

HDAC inhibitors (HDACi) arrest cell growth and leads to differentiation and apoptosis in tumor cells. HDACi can be divided into several structural classes including hydroxamic acids, cyclic peptides, aliphatic acids and benzamides etc. [@R08]-[@R09]. Naturally identified Hydroxamic acid HDAC inhibitor was Trichostatin A (TSA) and SAHA (Suberoylanilide hydroxamic acid or Vorinostat (Zolinza)) is structurally similar to TSA was first HDAC inhibitor approved for the treatment of refractory cutaneous T-cell lymphoma by Food and Drug Administration (FDA) in October 2006 [@R10]-[@R11]. The compounds with radio sensitizing properties were found to be effective in the clinical application as they are cell specific [@R12]. Research on the SAHA as HDAC inhibitor for the treatment of hematologic and solid tumors is found to be efficient [@R13]. Some studies found that HDAC inhibitors can be used for targeting the radio resistant cancers [@R14]. Trail (Apo2L, TNFSF10) as a mediator tigers the tumor cell death in acute myeloid leukemia [@R15]. Finding the specific HDACi for the individual HDAC is an important goal since HDACs are found to maintain different biological activities. Drug design is one of the emerging and important fields for drug discovery. The studies help in developing novel structures and potent drug molecules used for the drug therapies [@R16]. Studies on Uveal melanoma concluded that HDAC inhibitors provoked morphological differentiation which hindered the growth of tumor [@R17]. SAHA is a low toxic drug that was docked to get 12 different versions by drug modification and was screened. These were evaluated and were found to exhibit more potency and better affinity than the SAHA [@R18]. In order to develop best class of drugs, the innovative approach for drug designing, is opted by the researchers in recent times [@R19]. Optimization of HDAC2 inhibitors of hydroxamic acid was reported previously [@R20] and in this study we optimized hydroxamic acid group. Based on our previous QSAR and pharmacophore studies, molecular docking, binding energy and ADMET studies were carried out.

Methodology {#s2}
===========

Data set: {#s2a}
---------

Hydroxamic acids were optimized to improve the inhibitory activity towards HDAC2 protein. SAHA was chosen as reference structure to design new set of compounds. Total 96 compounds were designed based on the 3D-QSAR model on hydroxamic acid ([Figure 1](#F1){ref-type="fig"}) [@R22]. Hydroxamic acid derivatives were optimized with H-bond donors (OH, CH3, CH=CH2, Ph), hydrophobic (hydrocarbons - Pyrrole, Furan, Thiophene, Imidazole, Oxazole, Isooxzole, Benzene, Ph-NO2, Ph-COCH3, Ph-CCl3, Aniline, Indole, Pyridine and Pyrimidine) and electron withdrawing groups (NO2, NCH3, SO3CH3, COCl, COOH, COCH3, COH, Br, Cl and F) were listed in [Table 1](#T1){ref-type="table"}. Molecular docking analysis performed on these molecules to investigate for better HDAC2 inhibitors. All ligands were sketched using ISIS draw and given as input file in prepare ligand module in Discovery studio (DS). This generated 3Dstructures, tatuomers, and isomers and filtered the ligands by Lipinski rule of five. After applying the force fields on ligands the structures were minimized for lowest energy.

Protein preparation and docking: {#s2b}
--------------------------------

The crystal structure of HDAC2 (PDB ID: 3MAX) was downloaded from protein database (http://www.rcsb.org/pdb). The protein preparation was carried out in DS by removing water molecules and co-crystallized ligand further applying force filed parameter CHARMm to protein. The receptor binding sites were searched using flood filling algorithm. Docking calculations carried out using LibDock program implemented in discovery studio [@R01]. The 15 - site sphere was selected using coordinates in predefined binding site for docking studies. The 500 binding site features, so call \'HotSpots\' in binding site spheres were determined using a grid placed into the binding site with polar and apolar probes. The conformations of ligands poses were generated using FAST method and then placed into the binding site sphere. The docking poses were pruned and optimized. Final best optimized compounds were selected based on the LibDock score and H-bonds and the results were compared with the SAHA compound.

In 3D molecular docking studies, the candidate compound docked into the target protein and provides a variety of structural information such as hydrogen bonding interaction, electrostatic interaction, and molecular surface complementary and so on. The binding energy of complex calculated using Eq. 1, which gives the better understanding of binding affinity of the docked complex.

ΔE = E complex - (E enzyme + E ligand) (Eq. 1)

Best resulted compounds from molecular docking studies were considered for binding energy calculations. The energies of each inhibitor and HDAC2 were calculated by semi-empirical method PM6 [@R24]. The energy association of each ligand (ΔE) was estimated by three types of calculations such as (i) single point energy calculations of active site residues of protein and inhibitor complex (E complex) (ii) energy calculation of chosen active site residue of protein (E enzyme)and (iii) single point energy calculation on ligand (E ligand). The PM6 method used in this study because of the size of the complex and also the binding/interaction energies reported using PMx method shows good results [@R25]-[@R30]. The quantum chemical calculations were performed using GAUSSIAN 09 [@R31].

ADMET: {#s2c}
------

ADMET (Absorption, Distribution, Metabolism, and Excretion): In drug discovery many potential drugs failed in clinical trials or late drug discovery process, due to poor drug like properties and adverse side effects. In the current investigation, all the optimized hydroxamic acid compounds were subjected to ADMET studies to make sure toxicity risks and drug-relevant properties of molecules which are key factors, to determine drug-likeness of lead molecules. ADMET studies were conducted on selected lead compounds using Discovery Studio (Accelrys, San Diego, CA, USA). This module uses six mathematical models, to quantitatively predict properties by a set of rules/keys that specify threshold ADMET characteristics for the chemical structure of the molecules based on the available drug information.

Results and Discussion: {#s3}
=======================

Molecular docking: {#s3a}
------------------

Molecular docking studies were carried out on 96 designed hydroxamic acids from 3D-QSAR studies. The HDAC2 protein has 3 chains (Chain A, B and C), chain A is selected for docking studies [@R20], [@R32]. LibDock score, binding energy and H bonding considers for selection of best HDAC2 inhibitors. SAHA is chosen as reference compound for comparing the docking score of compounds. SAHA has the LibDock score of 126.37 dock score and 4 hydrogen bond interactions with ARG39(2), HIS183, GLY305, GLY154 amino acids and pi-pi interaction with PHE155. About 62 compounds among 96 were shown good docking score than SAHA, top listed 20 compounds with LibDock score and H-bonds were shown in [Table 2](#T2){ref-type="table"}. Based on molecular docking and H-bond interaction four compounds are selected as best inhibitor of HDAC2 protein. H34 (3-(8-oxo-8-(phenylamino) octanamido) benzoyl chloride) has the LibDock score of 153.22 and three Hbonds with ARG39, HIS146, GLY142 and pi-pi bond with ARG39 shown in [Figure 2 (b)](#F2){ref-type="fig"}, It shows oxygen of N-hydroxyl group forms H-bonds with HIS146, oxygen of formamide forms H-bonds with GLY142 and ARG39. LibDock score 145.94 for H81 (N1-(3-(pyridin- 2-yl)phenyl)-N8-vinyloctanediamide) with three H-bonds with ARG39, TYR308, HIS146 and pi-pi bond with ARG39 shown in [Figure 2(c)](#F1){ref-type="fig"}, it shows oxygen of N-hydroxyl group forms H-bonds with HIS146, oxygen of formamide forms H-bond with TYR308 and ARG39. H43 (N1-hydroxy-N8-(3-(thiophen-2-yl) phenyl) octanediamide) has LibDock score of 145.85 and five H-bonds with ARG39, GLN265 (2), HIS145, ASP181, ASP104 and pi-pi bond with ARG39 shown in [Figure 2(d)](#F1){ref-type="fig"}, It shows oxygen of N-hydroxyl group forms H-bonds with ASP104, oxygen of formamide forms H-bonds with ASP181, HIS145 and GLN265, thiophene of sulphar forms bonds with ARG39. H30 (N1-(3-fluorophenyl)-N8-vinyl octanediamide) has LibDock score of 143.00 with four H-bonds ARG39 (2), HIS183, GLY305, TRP140 and pi-pi bond with PHE155 shown in [Figure 2 (e)](#F1){ref-type="fig"}, It shows oxygen of N-hydroxyl group forms H-bonds with ARG39, GLY305 and TRP40 and oxygen of formamide forms H-bond with HIS183.The result shows that Nhydroxyl group, which is an important group and forms interactions with the HDAC2.

Binding Energy calculation: {#s3b}
---------------------------

Binding energy calculations were performed on the best 20 Compounds which have good docking score and H-bond interaction and results are listed in [Table 2](#T2){ref-type="table"}. In order to compare the obtained Binding energy (ΔE), calculations also performed on active HDAC2 inhibitors (SAHA). [Table 2](#T2){ref-type="table"} shows the binding energy calculation (PM6) of HDAC2-inhibitor complexes. The binding energy of active HDAC2 inhibitors SAHA is -33.25 kcal/mol, and the binding energy of selected four compounds as (3-(8-oxo-8-(phenylamino) octanamido)benzoyl chloride (H34) (- 39.53 kcal/mol), N1-(3-(pyridin-2-yl)phenyl)-N8- vinyloctanediamide (H81) (-56.08 kcal/mol), N1-hydroxy-N8-(3- (thiophen-2-yl)phenyl) octanediamide (H43) (-43.21 kcal/mol), N1- (3-fluorophenyl)-N8-vinyloctanediamide) (-35.76 kcal/mol), it shows these compounds have smaller binding energy than active HDAC2 inhibitors and were suggesting an inhibitors of HDAC2.The compounds, which are having hydrogen bond interactions with ARG, HIS, TYR active residues shows smaller binding energies. This implies that the active site residues ARG, HIS, TYR are become more favourable to the binding of HDAC2 inhibitors.

ADMET: {#s3c}
------

ADMET predictions were carried out to evaluate drug likeness of top 20 selected compounds and the properties were reported in [Table 3](#T3){ref-type="table"} together with biplot [Figure 3](#F1){ref-type="fig"}. The pharmacokinetic profiles of selected compounds were predicted by means of six precalculated ADMET model provided by Discovery studio. [Figure 3](#F1){ref-type="fig"} bi plot shows two analogous 95% and 99% confidence ellipse corresponding to HIA and BBB models. PSA have inverse relationship with human intestinal absorption and thus cell wall permeability. The log P used to estimate the lipophilicity, thus the information of H-bonding characteristics as obtained by calculating PSA could be taken into consideration along with logP calculation. The model with descriptors AlogP98 and PSA 2D with a bi-plot comprising 95% and 99% confidence ellipses was considered for the accurate prediction for the cell permeability of compounds. Selected 20 compounds had a good adsorption prediction for metabolism. In toxicity evaluation except H32 all compounds displayed CYP2D6 inhibiting and hepatotoxicity, suggesting that these compounds have no toxicity in the liver. Blood brain barrier (BBB) penetration showed that 10 compounds have good penetration; 8 compounds have low penetration and 2 compounds have undefined penetration;10 compounds may suitable for central nerve system therapy. Four compounds (3-(8-oxo-8- (phenylamino)octanamido)benzoyl chloride (H34); N1-(3-(pyridin- 2-yl)phenyl)-N8-vinyloctanediamide (H81);N1-hydroxy-N8-(3- (thiophen-2-yl)phenyl)octanediamide (H43); N1-(3-fluorophenyl)- N8-vinyloctanediamide) (H30) were selected as potential compounds based on the LibDock, binding energy, H bonding and ADMET properties.

Conclusion {#s5}
==========

It is of interest to identify better inhibitors for HDAC2. Here, we report the binding of 4 HDAC2 inhibitors with optimal LibDock score, binding energy and hydrogen-bonds. It is further noted by ADMET analysis that these compounds have good absorption, less toxic in the human liver and BBB penetration and may therefore suggest as HDAC2 inhibitors.
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###### Different substitutions used in hydroxamic acid derivatives

                   R1                           R1
  ----- ---------- ----------- ----- ---------- ------------
  H1    N-OH       NO2         H49   N-OH       Ph-COCH3
  H2    N-OH       NCH3        H50   N-OH       Ph-CCl3
  H3    N-OH       SO3CH3      H51   N-OH       Aniline
  H4    N-OH       COCl        H52   N-OH       Indole
  H5    N-OH       COOH        H53   N-OH       Pyridine
  H6    N-OH       COCH3       H54   N-OH       pyrimidine
  H7    N-OH       COH         H55   N-CH3      pyrrole
  H8    N-OH       Br          H56   N-CH3      furan
  H9    N-OH       Cl          H57   N-CH3      thiophene
  H10   N-OH       F           H58   N-CH3      Imidazole
  H11   N-CH3      NO2         H59   N-CH3      Oxazole
  H12   N-CH3      NCH3        H60   N-CH3      Isooxzole
  H13   N-CH3      SO3CH3      H61   N-CH3      Benzene
  H14   N-CH3      COCl        H62   N-CH3      Ph-NO2
  H15   N-CH3      COOR        H63   N-CH3      Ph-COCH3
  H16   N-CH3      COR         H64   N-CH3      Ph-CCl3
  H17   N-CH3      COH         H65   N-CH3      Aniline
  H18   N-CH3      Br          H66   N-CH3      Indole
  H19   N-CH3      Cl          H67   N-CH3      Pyridine
  H20   N-CH3      F           H68   N-CH3      pyrimidine
  H21   N-CH=CH2   NO2         H69   N-CH=CH2   pyrrole
  H22   N-CH=CH2   NCH3        H70   N-CH=CH2   furan
  H23   N-CH=CH2   SO3CH3      H71   N-CH=CH2   thiophene
  H24   N-CH=CH2   COCl        H72   N-CH=CH2   Imidazole
  H25   N-CH=CH2   COOR        H73   N-CH=CH2   Oxazole
  H26   N-CH=CH2   COR         H74   N-CH=CH2   Isooxzole
  H27   N-CH=CH2   COH         H75   N-CH=CH2   Benzene
  H28   N-CH=CH2   Br          H76   N-CH=CH2   Ph-NO2
  H29   N-CH=CH2   Cl          H77   N-CH=CH2   Ph-COCH3
  H30   N-CH=CH2   F           H78   N-CH=CH2   Ph-CCl3
  H31   N-Ph       NO2         H79   N-CH=CH2   Aniline
  H32   N-Ph       NCH3        H80   N-CH=CH2   Indole
  H33   N-Ph       SO3CH3      H81   N-CH=CH2   Pyridine
  H34   N-Ph       COCl        H82   N-CH=CH2   pyrimidine
  H35   N-Ph       COOR        H83   N-Ph       pyrrole
  H36   N-Ph       COR         H84   N-Ph       furan
  H37   N-Ph       COH         H85   N-Ph       thiophene
  H38   N-Ph       Br          H86   N-Ph       Imidazole
  H39   N-Ph       Cl          H87   N-Ph       Oxazole
  H40   N-Ph       F           H88   N-Ph       Isooxzole
  H41   N-OH       Pyrrole     H89   N-Ph       Benzene
  H42   N-OH       Furan       H90   N-Ph       Ph-NO2
  H43   N-OH       thiophene   H91   N-Ph       Ph-COCH3
  H44   N-OH       Imidazole   H92   N-Ph       Ph-CCl3
  H45   N-OH       Oxazole     H93   N-Ph       Aniline
  H46   N-OH       Isooxzole   H94   N-Ph       Indole
  H47   N-OH       Benzene     H95   N-Ph       Pyridine
  H48   N-OH       Ph-NO2      H96   N-Ph       pyrimidine

###### LibDock, Binding energy and H-bond interactions of hydroxamic acids

  Comp   LibDock Score   Binding Energy (Kcal/mol)   H-Bonds                                    H-Bond Monitor           H-Bond distance
  ------ --------------- --------------------------- ------------------------------------------ ------------------------ ------------------------------------------
  SAHA   126.37          -33.25                      ARG39(2), HIS183, GLY305, GLY154           P:ARG39:HH21 -L:O19      2.40, 2.14, 2.18, 2.46, 1.92
                                                                                                P:ARG39:HH22 - L:O18     
                                                                                                P:HIS183:HD1 - L:O10     
                                                                                                P:GLY305:HN - L:O18      
                                                                                                L:H25 - P:GLY154:O       
  H32    162.45          -18.78                      ARG39, GLY142                              P: ARG39: HH22 - L:O9    2.40, 2.18
                                                                                                L:H31 - P:GLY142:O       
  H51    153.359         -30.16                      HIS183, ASP181(2), TYR209, LEU276          P:HIS183:HD1 - L:O10     2.24, 2.12, 2.18, 1.78, 2.49
                                                                                                L:H33 - P:ASP181:OD1     
                                                                                                L:H33 - P:ASP181:OD2     
                                                                                                L:H45 - P:TYR209:OH      
                                                                                                L:H45 - P:LEU276:O       
  H34    153.221         -39.53                      ARG39, HIS146, GLY142                      P: ARG39:HH22 - L:O10    2.34, 2.20, 2.00
                                                                                                L:H28 - P:HIS146:NE2     
                                                                                                L:H30 - P:GLY142:O       
  H36    152.171         -36.9                       TYR29(2), HIS183, TYR29                    P:TYR29:HH - L:O9        2.31, 1.72, 2.04
                                                                                                P:HIS183:HD1 - L:O8      
                                                                                                L:H30 - P:TYR29:OH       
  H53    147.078         -39.72                      ARG39, GLY305, HIS146,                     P:ARG39:HH21 - L:O18     1.75, 2.12, 2.07, 2.39, 1.88
                                                     GLY142(2)                                  P:GLY305:HN - L:O19      
                                                                                                L:H30 - P:HIS146:NE2     
                                                                                                L:H43 - P:GLY142:O       
                                                                                                L: H44 - P:GLY142:O      
  H81    145.945         -56.08                      ARG39, TYR308, HIS146                      P:ARG39:HH21 - L:N5      1.81, 2.34, 2.03
                                                                                                P:TYR308:HH - L:O9       
                                                                                                L:H29 - P:HIS146:NE2     
  H43    145.859         -45.1                       ARG39, GLN265(2), HIS145, ASP181, ASP104   P:ARG39:HH21 - L:S24     2.44, 2.46, 2.14, 2.40, 2.07, 1.89
                                                                                                P:GLN265:HE21 - L:O10    
                                                                                                P:GLN265:HE22 - L:O10    
                                                                                                L:H31 - P:HIS145:NE2     
                                                                                                L:H31 - P:ASP181:OD1     
                                                                                                L:H43 - P:ASP104:OD2     
  H72    145.32          -10.3                       HIS183, TYR308                             L:H26 - P:HIS183:NE2     2.15, 2.02
                                                                                                L:H27 - P:TYR308:OH      
  H67    144.667         -8.4                        HIS183, GLY154                             P: HIS183:HD1 - L: O9    2.37, 1.91
                                                                                                L: H26 - P: GLY154:O     
  H74    144.355         -5.02                       ARG39, GLY305, GLY154, GLY142              P: ARG39:HH21 - L: N14   2.29, 2.49, 1.92, 1.73
                                                                                                P: GLY305: HN - L:O13    
                                                                                                L:H27 - P:GLY154:O       
                                                                                                L: H30 - P: GLY142:O     
  H54    144.304         -33.57                      ARG39, GLN265, GLY306, ASP181              P:ARG39:HH21 - L:N25     2.36, 2.35, 2.37, 1.90, 1.93
                                                                                                P:GLN265:HE22 - L:O10    
                                                                                                P:GLY306:HN - L:O10      
                                                                                                L:H32 - P:ASP181:OD1     
  H27    144.161         -40.78                      ARG39(3), HIS183(2), GLY305, GLY142        P:ARG39:HH21 -L:N7       2.27, 2.40, 2.45, 2.40, 1.95, 2.44, 1.74
                                                                                                P:ARG39:HH22 - L:O9      
                                                                                                P:ARG39:HH22 - L:O6      
                                                                                                P:HIS183:HD1 - L:O8      
                                                                                                P:HIS183:HD1 - L:O5      
                                                                                                P:GLY305:HN - L:O6       
                                                                                                L:H24 - P:GLY142:O       
  H46    143.584         -26.2                       ARG39, HIS145, GLY143, ASP104              P: ARG39:HH21 - L: N24   2.36, 2.46, 1.80, 2.21
                                                                                                P: HIS145: HN - L: O10   
                                                                                                L: H31 - P:GLY143:O      
                                                                                                L:H43 - P:ASP104:OD2     
  H37    143.211         -2.03                       ARG39 (2)                                  P:ARG39:HH21 - L:O6      2.31, 2.12
                                                                                                P:ARG39:HH22 - L:O6      
  H30    143.005         -35.76                      ARG39(2), HIS183, GLY305, TRP140           P:ARG39:HH21 - L:N8      2.16, 2.45, 2.13, 2.18, 1.85
                                                                                                P:ARG39:HH22 - L:O7      
                                                                                                P:HIS183:HD1 - L:O6      
                                                                                                P:GLY305:HN - L:O7       
                                                                                                L:H24 - P:TRP140:O       
  H26    142.892         -26.98                      ARG39, GLY305, TYR308, GLY142              P:ARG39:HH21 - L:N11     2.20, 2.40, 1.97, 1.73
                                                                                                P:GLY305:HN - L:O9       
                                                                                                L:H24 - P:TYR308:OH      
                                                                                                L:H26 - P:GLY142:O       
  H47    142.128         -36.92                      GLN265, GLY306, ASP181, ASP104             P:GLN265:HE22 - L:O10    2.45, 2.38, 2.05, 1.84
                                                                                                P:GLY306:HN - L:O10      
                                                                                                L:H32 - P:ASP181:OD1     
                                                                                                L:H44 - P:ASP104:OD2     
  H3     141.334         -20.6                       ARG39, TYR308, HIS183                      P:ARG39:HH21 - L:O22     1.75, 1.92, 2.09
                                                                                                P:TYR308:HH - L:O10      
                                                                                                L:H42 - P:HIS183:NE2     
  H69    141.308         -8.06                       TYR308, ALA141                             P:TYR308:HH - L:O12      2.17, 1.84
                                                                                                L:H26 - P:ALA141:O       
  H44    141.29          -57.1                       ARG39, TYR308, GLY142, ALA141, HIS183      P:ARG39:HH21 - L:O18     2.18, 1.93, 2.21, 1.82, 2.08
                                                                                                L:H29 - P:TYR308:OH      
                                                                                                L:H42 - P:GLY142:O       
                                                                                                L:H43 - P:ALA141:O       
                                                                                                L:H46 - P:HIS183:NE2     

###### ADMET prediction of top 20 optimized compounds

  Compound       aAbsorption   bBBB Level   cCYP2D6   dHepatotoxicity
  -------------- ------------- ------------ --------- -----------------
  Compound 3     0             4            1         0.509
  Compound 26    0             3            1         0.536
  Compound 27    0             3            1         0.509
  Compound 30    0             2            1         0.476
  Compound 32    0             2            0         0.582
  Compound 34    0             2            1         0.701
  Compound 36    0             2            1         0.688
  Compound 37    0             2            1         0.642
  Compound 43    0             2            1         0.602
  Compound 44    0             3            1         0.49
  Compound 46    0             3            1         0.437
  Compound 47    0             2            1         0.662
  Compound 51    0             4            1         0.682
  Compound 53    0             3            1         0.682
  Compound 54    0             3            1         0.655
  Compound 67    0             2            1         0.509
  Compound 69    0             2            1         0.596
  Compound 72    0             3            1         0.503
  Compound 74    0             3            1         0.443
  Compound 810   0             2            1         0.649

![Structural requirement for designing potent hydroxamic acids inhibitors](97320630015380F1){#F1}

![Docking poses of top four compounds (a) SAHA (b) (3-(8-oxo-8-(phenylamino)octanamido)benzoyl chloride (H34); (c) N1-(3- (pyridin-2-yl)phenyl)-N8-vinyloctanediamide (H81); (d) N1-hydroxy-N8-(3-(thiophen-2-yl)phenyl)octanediamide (H43); (e) N1-(3- fluorophenyl)-N8-vinyloctanediamide) (H30).](97320630015380F2){#F2}

![Plot of Polar Surface Area (PSA) vs. LogP for a standard and test set showing the 95% and 99% confidence limit ellipses corresponding to the Blood Brain Barrier and Intestinal Absorption models.](97320630015380F3){#F3}
